[
  {
    "Absolute_Carve-Outs": "- Absolute Carve-Outs refer to specific events or conditions that are explicitly excluded from constituting a Material Adverse Effect (MAE), thereby preventing them from being used as grounds to terminate or renegotiate an M&A agreement.\n- The identified carve-outs include changes in general economic, market, regulatory, or political conditions, including interest rates, exchange rates, tariffs, and trade wars.\n- General industry changes or developments, legal modifications, and changes in accounting standards (GAAP) are also excluded from triggering a MAE.\n- Events such as acts of war, terrorism, cyberterrorism (unless specifically targeting the company), weather events, natural disasters, epidemics, pandemics (including COVID-19), and other acts of God are carved out.\n- These exclusions shift risk allocation by preventing the buyer from citing these broad, external factors as a basis for claiming an MAE, thereby protecting the seller from potential renegotiations or deal terminations based on these factors."
  },
  {
    "Acquirer": "- The acquirer in the transaction is James Hardie Industries plc, a public company incorporated in Ireland.\n- James Hardie Industries plc acts as the parent of the Merger Sub in this transaction.\n- The acquirer is utilizing a Merger Sub for the transaction, although the name of the Merger Sub is not found.\n- Financing for the acquisition includes debt financing commitments from Bank of America, N.A. and Jeffries Finance LLC, cash on hand, and available amounts from the Parent Credit Facilities.\n- No guarantee or support agreement is associated with the acquirer for this transaction."
  },
  {
    "Best_Efforts": "- The \"Best Efforts\" standard required is \"reasonable best efforts,\" which applies across various provisions, including Covenants and Conditions to Closing.\n- The buyer (Parent and its Subsidiaries) must use reasonable best efforts to secure and consummate sufficient financing to complete the Merger, ensuring compliance with Debt Letters and satisfying conditions within their control.\n- The seller (Company) is obligated to cooperate with the buyer and utilize reasonable best efforts to facilitate the delisting of its stock from the NYSE promptly after the Effective Time, without voluntarily delisting before then.\n- Parties are required to cooperate and use reasonable best efforts to complete the transactions, including obtaining necessary approvals, making required filings, and defending against legal challenges.\n- No specific remedies for failure to perform, deadlines, limitations, or interactions with other covenants related to best efforts are identified in the provided data."
  },
  {
    "Board_Approval": "- Both the target and acquirer boards have approved the transaction, ensuring compliance with necessary representations, warranties, and conditions related to the merger.\n- The target board has included a recommendation to proceed with the merger, which is pertinent for shareholder voting and meeting mechanics.\n- Conditions for changing the target board's recommendation include receiving a superior proposal, an intervening event, or fulfilling board fiduciary duties.\n- The buyer must be notified before any change in the target board's recommendation, with a negotiation period of 4 business days required before such a change.\n- No board resolutions are required at closing, simplifying the post-closing process and reducing potential closing conditions."
  },
  {
    "Breach_Monitoring_and_Ongoing_Operations": "- Breach notifications are required as part of the obligations under covenants related to notification/publicity, notices, and termination.\n- The representations and warranties of the Parent and Merger Sub must be accurate as of the Closing Date, with certain allowances for minor inaccuracies, except where they could lead to a Material Adverse Effect on the Parent.\n- No provisions found regarding the rights to update disclosure schedules or a specified cure period for breaches.\n- There is no outlined termination right for breaches in the provided data.\n- The materiality standard for assessing breaches is defined as a Material Adverse Effect.\n- The buyer has rights to operational monitoring, allowing reasonable access to the company’s information and personnel for transaction preparation, provided it doesn't violate laws or legal privileges."
  },
  {
    "Clean_Room_Agreement": "- A Clean Room Agreement is not required according to the provided information.\n- There is no information found regarding the scope of clean room data, access restrictions, third-party administration, permitted use, or data destruction/return obligations.\n- Clean room restrictions are set to last until any termination of the agreement in accordance with its terms."
  },
  {
    "Closing": "- The closing is set to occur no later than the third business day after all conditions in Article VI are met or waived.\n- The closing will take place at the offices of Skadden, Arps, Slate, Meagher & Flom LLP in Chicago, Illinois.\n- No specific closing deliverables were identified for either the target or the acquirer.\n- There is no information on the timing for the effectiveness of the certificate of merger.\n- Prior to the Effective Time, the company must facilitate the resignation of its directors upon request, and certain individuals are to be appointed to the Parent Board upon the Effective Time."
  },
  {
    "Company_Material_Adverse_Change": "- The definition of \"Material Adverse Effect\" excludes events like changes in general economic or market conditions, regulatory changes, and acts of God, unless they have a disproportionate impact on the company compared to industry peers.\n- The \"Material Adverse Effect\" provision is not specified as a closing condition, nor is it used as a termination right.\n- No temporal scope or quantitative thresholds are provided for determining a Material Adverse Effect.\n- Cross-references to this section can be found in Sections 6.3(a), 6.3(b), 6.3(c), 6.2(a), 6.2(b), and 6.2(c).\n- The provision does not contain any unusual structural elements or specific carveouts related to the biotech industry."
  },
  {
    "Complete_Effects_on_Capital_Stock": "- Each share of Company Common Stock, except for Canceled and Dissenting Shares, will be canceled and converted to receive $26.45 per share in cash and a number of Parent Shares based on the Exchange Ratio.\n- Time-based restricted stock units for non-employee board members will fully vest and be canceled in exchange for the Merger Consideration, including accrued dividend equivalents.\n- Other restricted stock units will be assumed by Parent and converted into Parent stock units and cash awards, maintaining the original terms and conditions.\n- Fractional shares of Parent stock will be converted to cash equal to the value of the fractional share multiplied by the Parent Share Price.\n- The merger consideration consists of both cash and stock, with different treatment potentially applicable to different classes of stock."
  },
  {
    "Conditions_to_Closing": "- Shareholder approval is a condition for closing, indicating that the transaction needs the endorsement of shareholders.\n- Regulatory approval under the HSR Act is required, ensuring compliance with antitrust regulations.\n- There must be no legal restraints preventing the transaction, highlighting the need for a clear legal path to proceed.\n- The accuracy of representations is required, meaning the buyer's and target's statements must be true and without material adverse effects as of the closing date.\n- Compliance with covenants is necessary, ensuring both parties adhere to agreed business conduct before closing.\n- An officer’s certificate must be provided, verifying compliance and truthfulness of representations.\n- The absence of a material adverse effect is required, indicating no significant negative changes should affect the target or parent before closing.\n- A stock exchange listing condition must be met, ensuring that shares involved in the transaction are listed as required.\n- Financing is not a condition for closing, suggesting the transaction does not depend on securing additional financing.\n- Execution of ancillary agreements and third-party consents are not explicitly found, suggesting potential areas of uncertainty or negotiation."
  },
  {
    "Confidentiality_Agreement": "- The agreement references a pre-existing confidentiality agreement, indicating that prior confidentiality obligations are acknowledged.\n- The merger agreement does not supersede the existing confidentiality terms, implying continued adherence to the original confidentiality obligations.\n- Confidentiality obligations are designed to survive the termination of the agreement, ensuring ongoing protection of sensitive information even if the deal does not go through.\n- There is a provision for the return or destruction of confidential materials, highlighting the necessity to responsibly handle and dispose of sensitive information post-termination."
  },
  {
    "Covenants": "- The Company must provide reasonable access to its information for the Intended Purpose but can withhold information if disclosure violates laws or legal privileges.\n- Both parties are to use reasonable best efforts to close the transaction, including securing necessary financing and regulatory approvals.\n- Public announcements regarding the merger require prior consent from the other party unless legally required or consistent with specific disclosures.\n- The Company is restricted from soliciting or facilitating alternative acquisition proposals, unless necessary to fulfill fiduciary duties.\n- Shareholder meetings must be convened promptly for approval of the merger, with no additional proposals presented without Parent's consent.\n- Employment terms for Covered Employees should remain favorable or comparable to pre-merger conditions during a specified period.\n- Rights to indemnification for current or former directors and officers for pre-merger acts must be preserved post-closing.\n- Parent is committed to using reasonable best efforts to secure financing necessary to complete the merger.\n- Parties must notify each other of events that could jeopardize closing conditions or involve significant legal or regulatory communications.\n- Litigation related to the merger must be promptly reported, and settlements require Parent's consent."
  },
  {
    "Definitions_Section.csv": "- No summary could be generated due to insufficient information."
  },
  {
    "Dividends": "- Interim dividends are not allowed according to the document.\n- Buyer consent is not required for dividends.\n- Dividends do not adjust the merger consideration.\n- The right to receive dividends or distributions is included with each share of Parent Stock issued as merger consideration.\n- Information on special dividends, dividend cutoff dates, and the impact of dividends on proration or escrow is not found in the document."
  },
  {
    "Financing": "- Financing is required for the closing of the transaction, and this involves debt financing.\n- Commitment letters for the financing have been disclosed, but there is no equity commitment letter provided.\n- The buyer is expected to use \"reasonable best efforts\" to obtain the necessary financing.\n- Specific performance rights are not available, indicating limited legal recourse to enforce financing obligations.\n- There is no information available regarding the conditions to financing or the consequences of financing failure."
  },
  {
    "Guarantee": "- The section on \"Enforcement and Remedies\" specifies that parties are entitled to seek an injunction, specific performance, and other equitable relief to prevent breaches and enforce the agreement, alongside other legal or equitable remedies.\n- No information is available regarding the type of guarantee, cap amount, trigger events, non-recourse language, survival period, payment mechanics, or limitations on enforcement rights, making it impossible to generate a comprehensive summary of those aspects."
  },
  {
    "Guarantor": "- The section on the guarantor does not identify the guarantor's name, relationship to the acquirer, type of guarantee, scope of guarantee, or any cap or limitations on the guarantee.\n- The governing law for the guarantee is specified as the State of Delaware.\n- An equity commitment letter is not provided for the transaction.\n- Other details, such as the inclusion of a guarantee exhibit, are not found in the document."
  },
  {
    "Law_and_Jurisdiction": "- The governing law for the agreement is Delaware.\n- The Delaware Court of Chancery is the exclusive venue for any legal disputes, as indicated by the presence of an exclusive forum selection clause.\n- The agreement includes a waiver of the right to a jury trial.\n- There is no arbitration clause present, indicating that disputes will proceed directly to litigation.\n- The dispute resolution process is summarized as direct to litigation without preceding arbitration steps."
  },
  {
    "Merger_Agreement_Details": "- The agreement is titled \"Agreement and Plan of Merger,\" signed on March 23, 2025.\n- The merger involves James Hardie Industries plc as the parent party and The AZEK Company Inc. as the target party.\n- The structure involves a merger where a Merger Sub will merge with and into The AZEK Company Inc., making it a wholly-owned subsidiary of the parent.\n- The merger consideration will be a mix of cash and stock.\n- Delaware is the governing law for the agreement, with the parent party incorporated in Ireland and the Merger Sub in Delaware. The state of incorporation for the target is not specified."
  },
  {
    "No_Solicitation": "- The agreement does not include a go-shop period, meaning the company cannot actively seek other offers after signing.\n- The company is restricted from initiating or encouraging acquisition proposals, sharing non-public information, or engaging in discussions with third parties about potential deals, with limited exceptions for fiduciary duties.\n- A fiduciary out clause is present, allowing the company board to consider other offers if not doing so would breach their fiduciary duties.\n- Buyer matching rights are included, giving the current buyer an opportunity to match any superior proposal the company may receive.\n- There is a termination right for the company if a superior proposal is received, and a termination fee may be triggered if the company terminates the agreement for a competing deal.\n- Information on go-shop duration, conditions, and notice and negotiation requirements is not found in the provided data."
  },
  {
    "Ordinary_Course": "- The \"Ordinary Course\" is not explicitly defined in the document.\n- There is an operating covenant present that requires the business to be conducted in the ordinary course.\n- The ordinary course is not subject to a past practice standard, indicating flexibility from prior business practices.\n- Buyer consent is required for any deviation from conducting business in the ordinary course.\n- Compliance with the ordinary course requirements must be met using \"reasonable best efforts.\"\n- No information is provided on the consequences of breaching the ordinary course covenant."
  },
  {
    "Out_Date": "- The initial outside date for terminating the agreement is not found in the provided data.\n- There are no rights to extend the outside date, as indicated by the absence of extension rights.\n- Conditions to extend the outside date are not specified.\n- The mechanism for exercising any extension of the outside date is not found.\n- Information on which parties are allowed to terminate the agreement at the outside date is not found.\n- The maximum extended outside date is not found in the data provided."
  },
  {
    "Proxy_Statement": "- A proxy statement is required for the transaction, indicating that shareholder approval is necessary.\n- The proxy statement will be included as a prospectus in the registration statement on Form F-4, integrating it into statutory merger filings.\n- SEC review and clearance of the proxy statement are necessary before proceeding, making it a condition for closing the merger.\n- There is a representation that the information in the proxy statement is accurate, ensuring legal enforceability.\n- There is an obligation to update the proxy statement if necessary, indicating a commitment to provide current and correct information to shareholders."
  },
  {
    "R_W_Parent": "- Parent is a public limited company organized under Irish law and Merger Sub is a corporation organized under Delaware law.\n- Parent and Merger Sub have the necessary authority to execute and perform obligations under the Agreement, with required corporate actions duly authorized.\n- Execution and performance of the Agreement by Parent and Merger Sub do not conflict with their organizational documents or applicable laws, provided certain consents and filings are obtained.\n- Required consents and approvals include filings with the SEC, Registrar of Companies in Ireland, ASIC, and compliance with relevant stock exchange rules and Antitrust Laws.\n- No litigation is pending or threatened against Parent or its Subsidiaries that would have a material adverse effect on their ability to fulfill obligations under the Agreement.\n- Parent and its Subsidiaries are in compliance with applicable laws and permits, with no material adverse effects expected from non-compliance.\n- No investment banker, broker, or finder, apart from Jefferies LLC and BofA Securities, Inc., is entitled to fees in connection with the Agreement.\n- Parent has delivered true copies of debt commitment and fee letters to the Company, showing commitments from lenders for financing.\n- Parent Shares are duly authorized, validly issued, fully paid, nonassessable, and free of preemptive rights."
  },
  {
    "R_W_Target": "- The Company and its Subsidiaries are legally organized and have the authority to conduct business and own property, with exceptions not expected to materially affect the Merger.\n- The Company possesses the necessary corporate authority to execute and fulfill the obligations of the merger agreement, contingent upon obtaining stockholder approval.\n- Required consents and approvals include SEC filings, state securities laws compliance, and adherence to competition and antitrust laws, among others.\n- The Company has timely filed all required SEC documents and reports since September 30, 2023.\n- No pending or threatened legal proceedings are expected to materially affect the Company’s ability to perform its merger obligations."
  },
  {
    "Regulatory_Approvals": "- HSR Act clearance is required as a regulatory approval for the transaction.\n- Parties must use \"reasonable best efforts\" to obtain necessary regulatory approvals.\n- Filings under the HSR Act and other applicable Antitrust Laws must be made within 25 business days of the agreement, or as required by law.\n- There is a divestiture or remedy obligation present, but Parent and its Subsidiaries are not required to take actions affecting businesses or products of the Company with net sales exceeding $140,000,000 in the 2024 fiscal year.\n- Parties are committed to cooperating and using reasonable best efforts to obtain necessary consents and approvals, and to eliminate any impediments under Antitrust Law, including agreeing to Remedy Actions if required."
  },
  {
    "Regulatory_Obligations_Best_Efforts": "- The buyer is obligated to use \"reasonable best efforts\" to comply with regulatory obligations, indicating a strong but not absolute commitment to achieving regulatory approvals.\n- There is no specified standard for the seller's efforts regarding regulatory compliance.\n- The buyer is required to undertake divestitures or other remedies if necessary, demonstrating a willingness to adjust its business to meet regulatory requirements.\n- The \"hell or high water\" standard, which would require absolute commitment to fulfilling regulatory obligations, does not apply to the buyer.\n- There is a material adverse effect burden exception present, which may affect the buyer's obligations if significant negative changes occur."
  },
  {
    "Regulatory_Obligations_Timing": "- The initial regulatory filing deadlines are set to occur within twenty-five (25) business days following the date of the agreement.\n- No information is found regarding the timing for responding to agency requests.\n- There are no details provided on commitments for pulling and refiling regulatory documents.\n- The timing commitments for compliance with a second request are not specified.\n- There is no information found on the timing of foreign regulatory filings.\n- No details are available on the cooperation summary during a standstill period.\n- Extended review engagement obligations are not specified in the provided data."
  },
  {
    "Shareholder_Approval": "- Shareholder approval is required from the Company for the merger to proceed.\n- Approval must be obtained through a stockholder vote.\n- A majority of the outstanding shares of Company Common Stock entitled to vote is needed for approval.\n- Obtaining shareholder approval is a condition to closing the merger.\n- The Company's board must recommend the merger prior to shareholder approval.\n- Stockholder consent is not delivered at the signing of the agreement.\n- The timing for delivering the vote or consent is not specified.\n- Shareholders have appraisal rights available to them in connection with the merger."
  },
  {
    "Specific_Performance": "- Specific performance is available as a remedy, allowing a party to compel the other to fulfill their contractual obligations.\n- The right to specific performance is contingent upon all closing conditions being met.\n- Financing availability is not a prerequisite for seeking specific performance.\n- Both parties have mutual rights to seek specific performance.\n- Specific performance is not the exclusive remedy available; other legal remedies may also be pursued.\n- There are no identified limitations on the specific performance remedy within the provided data."
  },
  {
    "Termination": "- The agreement allows for termination due to a superior proposal.\n- Certain provisions survive termination, including the Confidentiality Agreement and specific sections outlined in the document.\n- A termination fee is triggered if the agreement is terminated under specific conditions, such as a breach or following an Acquisition Proposal.\n- No information was found regarding mutual termination rights, outside date termination rights, termination due to breach, or any regulatory block.\n- No details were provided about termination fees, reverse termination fees, or notice requirements."
  },
  {
    "Termination_Fees__Other_": "- No other termination fees are present in the agreement.\n- The description, amount, and triggers for any other termination fees were not found.\n- There is no specified cap for other termination fees."
  },
  {
    "Termination_Fees__Parent_to_Target_": "- The termination fee amount for the Parent to pay the Target is not specified.\n- Termination fees are triggered if a superior proposal is accepted, there is a change of recommendation, or the stockholder vote fails.\n- Termination fees are not applicable due to financing failure, regulatory failure, or a breach by the Parent.\n- The termination fee is the exclusive remedy available, meaning no further claims can be made beyond the fee.\n- There is no stated cap on the Parent's liability regarding the termination fee."
  },
  {
    "Termination_Fees__Target_to_Parent_": "- The termination fee amount payable by the target to the parent is not specified in the provided data.\n- The termination fee is triggered if a superior proposal is accepted, there is a change of board recommendation, or a stockholder vote fails.\n- The termination fee is applicable if a superior proposal is accepted, but not due to a change in the board's recommendation.\n- The termination fee serves as the exclusive remedy, meaning the parent cannot seek additional damages beyond this fee.\n- There are no specific performance rights preserved for the buyer, indicating the buyer cannot enforce the agreement beyond the termination fee."
  },
  {
    "Timeline": "- The signing date for the agreement is scheduled for March 23, 2025.\n- Stockholder vote or consent must occur within 50 days of the Form F-4 becoming effective.\n- Several timeline-related fields such as regulatory filing deadlines, marketing period end date, and outside date are not specified in the document.\n- Key terms such as no shop or go shop expiration, termination fee expiration date, and other material milestones are not provided.\n- No information is available regarding the confidentiality agreement signing date or the terms for extending the outside date."
  },
  {
    "Voting_Agreement": "- A voting agreement is not required for this transaction, as indicated by the field \"voting_agreement_required\" being set to false.\n- The lock-up or support agreement is effective until the earlier of the Effective Time or the termination of the Agreement as per Section 7.1.\n- Revocation rights are not available, meaning any commitments made in the voting agreement are not revocable.\n- No voting agreement parties, voting commitment summary, or coverage shares are identified, indicating insufficient information in these areas.\n- Voting agreements were not delivered at the signing of the agreement.\n- Remedies for breaches of the voting agreement include injunctions, specific performance, and other equitable relief, alongside any legal or equitable remedies available."
  }
]